DAO Gene
Gene Overview
<div class="infobox infobox-gene">
<div class="infobox-header">Gene Information</div>
| Gene Symbol | DAO |
|---|---|
| Full Name | D-Amino Acid Oxidase |
| Chromosomal Location | 12q24.11 |
| NCBI Gene ID | [1680](https://www.ncbi.nlm.nih.gov/gene/1680) |
| OMIM | [124050](https://www.omim.org/entry/124050) |
| Ensembl ID | [ENSG00000110888](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110888) |
| UniProt | [P14920](https://www.uniprot.org/uniprotkb/P14920/) |
| Associated Diseases | [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis), [Schizophrenia](/diseases/schizophrenia), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease) |
| Protein Class | Flavoenzyme, Peroxisomal enzyme |
| Expression | Brain (neurons, astrocytes), liver, kidney |
</div>
Overview
DAO (D-Amino Acid Oxidase) encodes a flavin adenine dinucleotide (FAD)-dependent enzyme that catalyzes the oxidative deamination of D-amino acids. This 347-amino acid peroxisomal enzyme is primarily known for its role in metabolizing [D-serine](/entities/d-serine), a key endogenous [NMDA receptor](/mechanisms/nmda-receptor-signaling) co-agonist critical for synaptic plasticity, learning, and memory[@van2014]. DAO is expressed throughout the brain with particularly high levels in the [cerebral cortex](/brain-regions/cerebral-cortex), [hippocampus](/brain-regions/hippocampus), [cerebellum](/brain-regions/cerebellum), and spinal cord[@morikawa2001].
...DAO Gene
Gene Overview
<div class="infobox infobox-gene">
<div class="infobox-header">Gene Information</div>
| Gene Symbol | DAO |
|---|---|
| Full Name | D-Amino Acid Oxidase |
| Chromosomal Location | 12q24.11 |
| NCBI Gene ID | [1680](https://www.ncbi.nlm.nih.gov/gene/1680) |
| OMIM | [124050](https://www.omim.org/entry/124050) |
| Ensembl ID | [ENSG00000110888](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000110888) |
| UniProt | [P14920](https://www.uniprot.org/uniprotkb/P14920/) |
| Associated Diseases | [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis), [Schizophrenia](/diseases/schizophrenia), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease) |
| Protein Class | Flavoenzyme, Peroxisomal enzyme |
| Expression | Brain (neurons, astrocytes), liver, kidney |
</div>
Overview
DAO (D-Amino Acid Oxidase) encodes a flavin adenine dinucleotide (FAD)-dependent enzyme that catalyzes the oxidative deamination of D-amino acids. This 347-amino acid peroxisomal enzyme is primarily known for its role in metabolizing [D-serine](/entities/d-serine), a key endogenous [NMDA receptor](/mechanisms/nmda-receptor-signaling) co-agonist critical for synaptic plasticity, learning, and memory[@van2014]. DAO is expressed throughout the brain with particularly high levels in the [cerebral cortex](/brain-regions/cerebral-cortex), [hippocampus](/brain-regions/hippocampus), [cerebellum](/brain-regions/cerebellum), and spinal cord[@morikawa2001].
The enzyme's activity has profound implications for neurodegenerative and psychiatric disorders. Elevated DAO activity has been documented in amyotrophic lateral sclerosis (ALS), where it contributes to D-serine depletion and subsequent NMDA receptor dysfunction[@sasabe2007]. Genetic variations in the DAO gene have been robustly associated with schizophrenia risk, positioning DAO as a nexus between glutamatergic signaling and psychiatric disease[@burnet2011]. Recent research has also revealed connections to [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), where altered D-serine metabolism may contribute to excitotoxic mechanisms[@lin2016][@wu2019].
Gene Structure and Regulation
The human DAO gene spans approximately 18.5 kb on chromosome 12q24.11 and comprises 13 coding exons. The promoter region contains multiple regulatory elements controlling tissue-specific expression, including a peroxisome proliferator response element (PPRE) and binding sites for transcription factors involved in neuronal specification.
Transcript Variants
Multiple DAO transcript variants have been characterized:
| Variant | Description | Tissue Distribution |
|---------|-------------|---------------------|
| DAO-001 | Full-length canonical transcript | Brain, liver, kidney |
| DAO-002 | Alternative exon 1 usage | Brain-specific |
| DAO-003 | Truncated variant | Testis |
Epigenetic Regulation
DAO expression is subject to epigenetic control:
DNA Methylation: The DAO promoter shows differential methylation in schizophrenia patients
Histone Modifications: H3K27ac marks active enhancers in neuronal cells
Non-coding RNAs: Several microRNAs target DAO mRNA for degradationProtein Structure and Biochemistry
DAO is a 39 kDa FAD-dependent flavoenzyme localized primarily to peroxisomes. The enzyme adopts a classical TIM-barrel fold with the active site positioned at the C-terminal end of the barrel.
Mermaid diagram (expand to render)
Catalytic Mechanism
DAO catalyzes the oxidative deamination of D-amino acids through a classical flavin-mediated mechanism:
Substrate Binding: D-amino acid enters the active site pocket
Oxidation: FAD reduces the substrate, forming an imine intermediate
Hydrolysis: The imine hydrolyzes to yield α-keto acid and ammonia
Regeneration: FAD is reoxidized by molecular oxygen, producing H<sub>2</sub>O<sub>2</sub>Substrate Specificity
While DAO can metabolize various D-amino acids, its preferred physiological substrate is D-serine. The enzyme exhibits varying affinity for:
- D-Serine: K<sub>m</sub> ≈ 3-5 mM (primary physiological substrate)
- D-Alanine: K<sub>m</sub> ≈ 10-15 mM
- D-Phenylalanine: K<sub>m</sub> ≈ 8 mM
- D-Proline: Poor substrate
Tissue Distribution
| Brain Region | DAO Expression Level | Cell Type |
|--------------|---------------------|-----------|
| Cerebral Cortex | High | Pyramidal neurons, astrocytes |
| Hippocampus | High | CA1-CA3 pyramidal cells |
| Cerebellum | High | Granule cells |
| Brainstem | Moderate | Motor neurons |
| Spinal Cord | High | Motor neurons |
| Basal Ganglia | Moderate | GABAergic neurons |
Normal Physiological Functions
The primary physiological role of DAO in the brain is regulation of D-serine levels. D-serine is synthesized by [serine racemase](/enzymes/serine-racemase) and serves as the predominant endogenous co-agonist for NMDA receptors, surpassing glycine in this role in most brain regions[@mothet2005].
The DAO-D-serine relationship is crucial for:
Synaptic Plasticity: D-serine availability modulates NMDA receptor-dependent LTP and LTD
Learning and Memory: Spatial memory formation requires appropriate D-serine tone
Cellular Resilience: NMDA receptor activation promotes neuronal survival during development
Circuit Refinement: Activity-dependent synaptic pruning requires precise NMDAR timingMermaid diagram (expand to render)
Peroxisomal Function and Redox Homeostasis
DAO contributes to peroxisomal metabolism and cellular redox balance:
Amino Acid Catabolism: Provides carbon skeletons for energy metabolism
Hydrogen Peroxide Production: Generates H<sub>2</sub>O<sub>2</sub> as a signaling molecule
Detoxification: Processes D-amino acids from diet and protein turnover
Lipid Metabolism: Peroxisomes also host β-oxidation of very-long-chain fatty acidsNeuroprotective vs. Neurotoxic Balance
DAO's role in neurodegeneration is context-dependent:
| Condition | DAO Activity | Outcome |
|-----------|--------------|---------|
| Normal aging | Moderate | Maintenance of D-serine homeostasis |
| ALS | Elevated | D-serine depletion, NMDAR dysfunction |
| Schizophrenia | Variable (genotype-dependent) | Altered NMDAR signaling |
| AD | Dysregulated | Excitotoxicity contribution |
Disease Associations
Amyotrophic Lateral Sclerosis (ALS)
DAO is strongly implicated in ALS pathogenesis through multiple mechanisms[@sasabe2007]:
Evidence for DAO Involvement
- Elevated DAO Activity: Post-mortem ALS motor cortex and spinal cord show increased DAO
- D-Serine Depletion: ALS patients exhibit reduced cerebrospinal fluid D-serine
- Genetic Linkage: DAO polymorphisms modify ALS risk and age of onset
- SOD1 Interaction: Mutant SOD1 interacts with DAO, potentially altering its activity
Mechanistic Pathways
Mermaid diagram (expand to render)
Therapeutic Implications
- DAO Inhibitors: Sodium benzoate and other DAO inhibitors show promise
- D-Serine Supplementation: May restore NMDAR function
- Gene Therapy: AAV-mediated DAO knockdown in development
Schizophrenia
DAO is one of the most robustly validated schizophrenia risk genes[@burnet2011][@straub2018]:
Genetic Evidence
- GWAS Signal: DAO polymorphisms showgenome-wide significant association
- Linkage Studies: DAO region linked to schizophrenia in multiple families
- Haplotype Risk: Specific haplotypes confer 1.3-1.5x increased risk
The D-Serine Hypothesis
Mermaid diagram (expand to render)
- Functional SNPs: rs3741770, rs1013442, rs2070586 alter DAO activity
- Expression QTLs: Risk haplotypes associate with reduced DAO mRNA
- Interaction Effects: DAO × GRM3 epistatic interaction affects risk
Alzheimer's Disease
Emerging evidence links DAO to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis[@lin2016]:
Evidence
- Altered D-Serine: AD patients show elevated brain D-serine
- DAO Expression: Variable changes in AD brain regions
- Genetic Association: Some DAO SNPs modify AD risk
- Interaction with Tau: D-serine may influence tau pathology
Potential Mechanisms
Excitotoxicity: Excessive D-serine could contribute to excitotoxic stress
Synaptic Dysfunction: NMDAR-mediated calcium dysregulation
Neuroinflammation: DAO-generated H<sub>2</sub>O<sub>2</sub> as inflammatory signalParkinson's Disease
DAO may contribute to [Parkinson's disease](/diseases/parkinsons-disease) through dopaminergic system effects[@wu2019]:
- D-Serine in PD Models: D-serine exacerbates toxin-induced parkinsonism
- NMDAR in PD: NMDAR antagonists protect dopaminergic neurons
- DAO Inhibition: May provide neuroprotection in PD models
Other Neurological Conditions
| Condition | DAO Relationship | Evidence Level |
|-----------|-----------------|-----------------|
| Epilepsy | Altered D-serine metabolism | Moderate |
| Huntington's Disease | NMDAR-mediated excitotoxicity | Preliminary |
| Bipolar Disorder | D-serine dysregulation | Moderate |
| Major Depression | DAO expression changes | Limited |
Therapeutic Targeting
DAO Inhibitors
Several DAO inhibitors have been explored therapeutically[@honey2017]:
| Compound | Status | Mechanism | Challenges |
|----------|--------|-----------|------------|
| Sodium Benzoate | Phase II trials | Direct DAO inhibition | Limited brain penetration |
| 3,3'-Diaminobenzidine | Preclinical | Irreversible inhibition | Toxicity |
| Phenyloxacetic acid derivatives | Preclinical | Competitive inhibition | Specificity |
| AS056 | Preclinical | Selective inhibition | Not yet in trials |
D-Serine-Based Therapies
Since DAO degrades D-serine, supplementation strategies include:
D-Serine Administration: Clinical trials for schizophrenia (mixed results)
D-Alanine: Alternative NMDAR co-agonist
Glycine Transport Inhibitors: Increase synaptic glycine (NMDAR co-agonist)Genetic and Molecular Approaches
- Antisense Oligonucleotides: Targeting DAO mRNA
- CRISPR-Based Editing: Potential for DAO regulation
- Gene Therapy: AAV-mediated DAO modulation
Clinical Considerations
- Biomarkers: CSF D-serine as pharmacodynamic marker
- Combination Therapy: DAO inhibitors + D-serine (replacement)
- Personalized Medicine: DAO genotype-guided treatment
Research Directions and Knowledge Gaps
Outstanding Questions
Cell-Type Specificity: How does DAO function differ in neurons vs. astrocytes?
Developmental Role: What is DAO's role in brain development?
Compensation Mechanisms: How do other D-serine sources compensate when DAO is inhibited?
Substrate Switching: Can DAO be modulated to preferentially use different substrates?
Therapeutic Window: What is the optimal level of DAO inhibition?Emerging Research Areas
- Single-Cell Analysis: Cell-type specific DAO expression patterns
- Structural Biology: DAO-inhibitor complex structures for drug design
- Biomarkers: D-serine as diagnostic or prognostic marker
- Blood-Brain Barrier: Improving DAO inhibitor delivery
Enzymes and Proteins
- [Serine Racemase](/enzymes/serine-racemase) - D-serine synthesis
- [NMDA Receptor](/mechanisms/nmda-receptor-signaling) - D-serine target
- [FAD Synthetase](/enzymes/fad-synthetase) - Cofactor metabolism
- [SOD1](/genes/sod1) - ALS interaction
Pathways
- [Glutamatergic Signaling](/mechanisms/glutamatergic-signaling)
- [NMDA Receptor Signaling](/mechanisms/nmda-receptor-signaling)
- [Peroxisomal Metabolism](/mechanisms/peroxisomal-pathway)
- [Excitotoxicity](/mechanisms/excitotoxicity)
Diseases
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Schizophrenia](/diseases/schizophrenia)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Epilepsy](/diseases/epilepsy)
Molecules
- [D-Serine](/entities/d-serine)
- [L-Serine](/entities/l-serine)
- [FAD](/entities/fad)
- [Glycine](/entities/glycine)
Key Publications
[Burnet PW, et al. D-amino acid oxidase in schizophrenia (2011)](https://pubmed.ncbi.nlm.nih.gov/21324941/)
[Sasabe J, et al. D-serine and D-amino acid oxidase in ALS (2007)](https://pubmed.ncbi.nlm.nih.gov/17415985/)
[Van Vliet T, et al. DAO and NMDA receptor signaling (2014)](https://pubmed.ncbi.nlm.nih.gov/24389459/)
[Morikawa A, et al. D-serine metabolism in brain (2001)](https://pubmed.ncbi.nlm.nih.gov/11267608/)
[Fukushima T, et al. D-amino acid oxidase functions (2004)](https://pubmed.ncbi.nlm.nih.gov/14741744/)
[Katagiri M, et al. D-amino acid oxidase in neuropsychiatric diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/29195078/)
[O'Brien KB, et al. DAO activity and mutant SOD1 in ALS (2010)](https://pubmed.ncbi.nlm.nih.gov/20075673/)
[Paul BD, et al. D-Serine regulation of NMDA receptor (2019)](https://pubmed.ncbi.nlm.nih.gov/31712774/)
[Lin CH, et al. DAO polymorphisms and Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27589514/)
[Straub RE, et al. DAO genetic variation and brain function (2018)](https://pubmed.ncbi.nlm.nih.gov/29274762/)
[Honey LJ, et al. DAO inhibitors as therapeutic agents (2017)](https://pubmed.ncbi.nlm.nih.gov/28545386/)
[Wu J, et al. D-Serine in Parkinson's disease models (2019)](https://pubmed.ncbi.nlm.nih.gov/31149789/)External Resources
- [NCBI Gene: DAO](https://www.ncbi.nlm.nih.gov/gene/1680)
- [UniProt: DAO (P14920)](https://www.uniprot.org/uniprotkb/P14920/)
- [GeneCards: DAO](https://www.genecards.org/cgi-bin/carddisp.pl?gene=DAO)
- [OMIM: 124050](https://www.omim.org/entry/124050)
- [Human Protein Atlas: DAO](https://www.proteinatlas.org/ENSG00000110888-DAO)
- [KEGG: D-Amino Acid Oxidase Pathway](https://www.genome.jp/pathway/map00271)
Last updated: 2026-03-25References
[Burnet PW, et al, D-amino acid oxidase in schizophrenia (2011)](https://pubmed.ncbi.nlm.nih.gov/21324941/)
[Sasabe J, et al, D-serine and D-amino acid oxidase in ALS (2007)](https://pubmed.ncbi.nlm.nih.gov/17415985/)
[Van Vliet T, et al, DAO and NMDA receptor signaling (2014)](https://pubmed.ncbi.nlm.nih.gov/24389459/)
[Morikawa A, et al, D-serine metabolism in brain (2001)](https://pubmed.ncbi.nlm.nih.gov/11267608/)
[Fukushima T, et al, D-amino acid oxidase functions (2004)](https://pubmed.ncbi.nlm.nih.gov/14741744/)
[Katagiri M, et al, D-amino acid oxidase and D-serine in neuropsychiatric diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/29195078/)
[Billard JM, D-serine in the aging brain (2012)](https://pubmed.ncbi.nlm.nih.gov/23091461/)
[Mothet JP, et al, D-Serine is a key neuromodulator (2005)](https://pubmed.ncbi.nlm.nih.gov/16568465/)
[O'Brien KB, et al, DAO activity and mutant SOD1 in ALS (2010)](https://pubmed.ncbi.nlm.nih.gov/20075673/)
[Paul BD, et al, D-Serine regulation of NMDA receptor and its implications in disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31712774/)
[Lin CH, et al, DAO polymorphisms and Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27589514/)
[Straub RE, et al, DAO genetic variation and brain function (2018)](https://pubmed.ncbi.nlm.nih.gov/29274762/)
[Honey LJ, et al, DAO inhibitors as therapeutic agents (2017)](https://pubmed.ncbi.nlm.nih.gov/28545386/)
[Ferraris M, et al, D-Serine and DAO in psychiatric disorders (2018)](https://pubmed.ncbi.nlm.nih.gov/29493403/)
[Davies JP, et al, DAO deficiency and neurodevelopment (2018)](https://pubmed.ncbi.nlm.nih.gov/29438597/)
[Wu J, et al, D-Serine in Parkinson's disease models (2019)](https://pubmed.ncbi.nlm.nih.gov/31149789/)Pathway Diagram
The following diagram shows the key molecular relationships involving DAO Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)